Accumulation of Krebs cycle intermediates and over-expression of HIF1?? in tumours which result from germline FH and SDH mutations, Human Molecular Genetics, vol.14, issue.15, pp.2231-2239, 2005. ,
DOI : 10.1093/hmg/ddi227
Fumarase: A Mitochondrial Metabolic Enzyme and a Cytosolic/Nuclear Component of the DNA Damage Response, PLoS Biology, vol.452, issue.3, p.1000328, 2010. ,
DOI : 10.1371/journal.pbio.1000328.s003
Targeting mTOR in renal cell carcinoma, Cancer, vol.22, issue.18S, pp.2313-2320, 2009. ,
DOI : 10.1002/cncr.24239
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-456, 2008. ,
DOI : 10.1016/S0140-6736(08)61039-9
Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.25, issue.25, pp.3958-3964, 2007. ,
DOI : 10.1200/JCO.2006.10.5916
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, 2007. ,
DOI : 10.1056/NEJMoa066838
Prognostic relevance of the mTOR pathway in renal cell carcinoma, Cancer, vol.9, issue.11, pp.2257-2267, 2007. ,
DOI : 10.1002/cncr.22677
Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma, Clinical Genitourinary Cancer, vol.5, issue.6, pp.379-385, 2007. ,
DOI : 10.3816/CGC.2007.n.020
Analysis of PTEN and HIF-1?? and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-??, Cancer, vol.7, issue.16, pp.3651-3660, 2009. ,
DOI : 10.1002/cncr.24438
Differential Dependence of Hypoxia-inducible Factors 1?? and 2?? on mTORC1 and mTORC2, Journal of Biological Chemistry, vol.283, issue.50, pp.34495-34499, 2008. ,
DOI : 10.1074/jbc.C800170200
Deficiency of FLCN in Mouse Kidney Led to Development of Polycystic Kidneys and Renal Neoplasia, PLoS ONE, vol.4, issue.10, p.3581, 2008. ,
DOI : 10.1371/journal.pone.0003581.s003
The role of the Birt-Hogg-Dub protein in mTOR activation and renal tumorigenesis é ,
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2, Proceedings of the National Academy of Sciences, vol.106, issue.44, pp.18722-18727, 2009. ,
DOI : 10.1073/pnas.0908853106
Renal tumour suppressor function of the Birt-Hogg-Dub syndrome gene product folliculin é, J ,
The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma, Clinical Genetics, vol.18, issue.3, pp.184-191, 2003. ,
DOI : 10.1034/j.1399-0004.2003.00035.x
HIF-?? Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma, Cancer Cell, vol.14, issue.6, pp.435-446, 2008. ,
DOI : 10.1016/j.ccr.2008.10.016
Detection of DNA Copy Number Changes and Oncogenic Signaling Abnormalities from Gene Expression Data Reveals MYC Activation in High-Grade Papillary Renal Cell Carcinoma, Cancer Research, vol.67, issue.7, pp.3171-3176, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-4571
EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE, The Journal of Urology, vol.172, issue.4, pp.1256-1261, 2004. ,
DOI : 10.1097/01.ju.0000139583.63354.e0
Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma, Clinical Cancer Research, vol.15, issue.4 ,
DOI : 10.1158/1078-0432.CCR-08-1229
c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations, Journal of Biological Chemistry, vol.283, issue.5, pp.2675-2683, 2008. ,
DOI : 10.1074/jbc.M705774200
Dependence receptors: a new paradigm in cell signaling and cancer therapy, Oncogene, vol.17, issue.13, pp.1865-1882, 2010. ,
DOI : 10.1016/S0959-8049(97)00309-2
URL : https://hal.archives-ouvertes.fr/hal-00474454
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen, Proceedings of the National Academy of Sciences, vol.105, issue.43, pp.16484-16489, 2008. ,
DOI : 10.1073/pnas.0806574105
Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis, The FASEB Journal, vol.24, issue.8, pp.9-146928, 1096. ,
DOI : 10.1096/fj.09-146928
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma, Cancer J Sci Am, vol.6, pp.55-57, 2000. ,
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.23, issue.1, pp.133-141, 2005. ,
DOI : 10.1200/JCO.2005.03.206
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer, Clinical Cancer Research, vol.11, issue.10 ,
DOI : 10.1158/1078-0432.CCR-04-2019
Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer, The Journal of Urology, vol.179, issue.2, pp.730-736, 2008. ,
DOI : 10.1016/j.juro.2007.09.016
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.17, issue.8, pp.2530-2540, 1999. ,
DOI : 10.1200/JCO.1999.17.8.2530
Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.23, issue.4, pp.832-841, 2005. ,
DOI : 10.1200/JCO.2005.05.179